
Cimed is owned by Cimed & Co., the holding company of the family-controlled Grupo Cimed, headquartered in Pouso Alegre, Minas Gerais, Brazil. Founded in 1977 by João Adibe Marques de Oliveira, the group is still controlled by the Adibe Marques family and led by second-generation CEO João Adibe. It is privately held and reported net revenue of approximately R$3.07 billion in 2025.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cimed | Cimed & Co. | Wholly owned |
Cimed was founded in 1977 by João Adibe Marques de Oliveira in Marília, in the state of São Paulo, Brazil. It began as a pharmaceutical distribution and marketing business before expanding into manufacturing its own medicines and health products.
Through the following decades the company built a broad portfolio of over-the-counter medicines, generics, and consumer health products, establishing manufacturing operations and relocating its center of gravity to Pouso Alegre in Minas Gerais. It grew into one of the largest pharmaceutical companies in Brazil, a position built largely on high-volume OTC and consumer products rather than patented prescription drugs.
The company's best-known brands became household names in Brazil. Carmed lip balm, Cimegripe cold and flu products, and the Lavitan vitamin line gave Cimed a consumer-facing profile unusual for a Brazilian pharma company, and it backed that profile with heavy marketing, including a long-running sponsorship presence in Stock Car Brasil racing.
Under second-generation CEO João Adibe, the group pushed further into consumer goods and brand building, aiming to turn Cimed from a medicines company into what it calls Brazil's largest health and consumer company. In 2025 it reported net revenue of approximately R$3.07 billion, up 12.5 percent on the prior year, though net income fell about 30 percent to R$196.7 million amid higher costs and a difficult SAP S/4HANA implementation that temporarily disrupted its commercial operation. By the first quarter of 2026 it reported roughly R$1 billion in quarterly revenue, up 20 percent year over year, and a stated ambition to reach R$10 billion in annual revenue by 2030.
What does Cimed & Co. own?
Cimed & Co. controls Grupo Cimed's pharmaceutical and consumer health businesses, including brands such as Carmed, Cimegripe, and Lavitan, plus a large OTC and generic medicines portfolio and an expanding consumer goods operation.
Is Cimed & Co. publicly traded?
No. It is a privately held, family-controlled holding company with no stock listing. It does publish consolidated financial statements.
Who founded Cimed & Co.?
The group was founded in 1977 by João Adibe Marques de Oliveira in Marília, São Paulo. It is now led by second-generation CEO João Adibe, with third-generation family members entering senior leadership.
Where is Cimed & Co. headquartered?
The group is headquartered in Pouso Alegre, Minas Gerais, Brazil, where its main manufacturing and administrative operations are concentrated.
Who owns Cimed & Co.?
The company is controlled by the Adibe Marques family across three generations. There are no disclosed outside institutional shareholders.
What is Cimed's financial performance?
In 2025 it reported net revenue of approximately R$3.07 billion, up 12.5 percent, and net income of R$196.7 million, down about 30 percent. It reported about R$1 billion in revenue in the first quarter of 2026 and targets R$10 billion annually by 2030.
Cimed is a pharmaceutical manufacturer, so its ethics profile centers on drug quality, safety, and regulatory compliance rather than consumer certifications like cruelty-free or B Corp status, none of which are documented for the company as of November 2026.
The more relevant frameworks are Brazilian health regulation and manufacturing standards. As a domestic drugmaker it operates under ANVISA oversight for product registration, good manufacturing practices, and pharmacovigilance. Its growing consumer goods line adds ordinary consumer-product obligations. No major independently verified sustainability certification or flagship environmental commitment was documented at the time of writing.
Cimed has faced the standard regulatory exposure of a large pharmaceutical manufacturer but had no dominant public scandal on record as of November 2026.
The most discussed issue in recent coverage is financial rather than ethical: in 2025 the company's profit fell about 30 percent to R$196.7 million even as revenue grew, and analysts noted pressure on cash generation. Management attributed part of the year's difficulty to temporary disruption from a major SAP S/4HANA implementation and to internal limitations it moved to address. Separately, the group has periodically appeared in coverage of Brazil's competitive and sometimes litigious pharmaceutical market, but no major product recall or regulatory sanction defined its public record at the time of writing.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Adcock Ingram | South Africa | 1891 | Mass market | Regional | All Genders | |
| Boehringer Ingelheim | Germany | 1885 | Market leader | Global | All Genders | |
| Haleon | United Kingdom | 2022 | Mass market | Global | All-ages | |
| Kenvue | USA | 2023 | Mass market | Global | All Genders |
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
Healthcare PharmaceuticalsOwned by Haleon plc
Consumer healthcare brand and company name of the world's largest pure-play consumer health business, owner of Sensodyne, Advil, Panadol, and Centrum.
Household Consumer GoodsOwned by Kenvue
Consumer health brand of Kenvue, the company behind Tylenol, Listerine, Band-Aid, and Neutrogena, now a wholly owned subsidiary of Kimberly-Clark following a November 2026 acquisition.
Market Positioning: Cimed competes with 4 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Cimed & Co., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
Boehringer Ingelheim operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Haleon plc
Consumer healthcare brand and company name of the world's largest pure-play consumer health business, owner of Sensodyne, Advil, Panadol, and Centrum.
Haleon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by ADARx Pharmaceuticals, Inc.
Biotechnology brand of ADARx Pharmaceuticals, the San Diego siRNA company that listed on Nasdaq in September 2026.
ADARx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Amgen operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.